Duopharma concludes supply deal for 6.4m doses of Sputnik V vaccine


Duopharma Biotech said the supply of the 6.4 million doses of the Sputnik V vaccine is subject to the approval by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

KUALA LUMPUR: Duopharma Biotech Bhd has concluded the supply agreements with the Malaysian Government and Russian Direct Investment Fund (RDIF) for the supply of 6.4 million doses of the Sputnik V vaccine.

In a statement on Tuesday, it said the supply of the vaccine is subject to the approval of the vaccine by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

The Star Christmas Special Promo: Save 35% OFF Yearly. T&C applies.

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Australia dollar suffers with stocks, kiwi underwhelmed by GDP
Oil prices jump�on Trump's Venezuela blockade
Ringgit opens near five-year high at 4.07 vs US$
FBM KLCI edges down at open as consolidation pressures remain
Trading ideas: Gamuda, Paramount, Jati Tinggi, Muhibbah, Silver Ridge, TSR Capital, Itmax, Globaltec, Prestar, Apex Healthcare, YNHP, Top Glove, Scientex, Hi Mobility
Oil rises as Trump's Venezuela blockade eases crude surplus concerns�
Firmer ringgit, steady equity gains in 2026
Bursa ends lower on profit-taking after four-day rally�
MEB sells supply vessel for RM74mil
Gamuda’s Australian JV wins RM2.69bil package

Others Also Read